ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO559

Hypereosinophilia in Haemodialysis Patients

Session Information

Category: Trainee Case Report

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Griffiths, Kathryn Jane, Epsom and St Helier University Hospital NHS Trust, London, United Kingdom
  • Makanjuola, David, Epsom and St Helier University Hospital NHS Trust, London, United Kingdom
  • Austin, Michael J., Epsom and St Helier University Hospital NHS Trust, London, United Kingdom
  • De lord, Corinne Frances mary, Epsom and St Helier University Hospital NHS Trust, London, United Kingdom
  • Cheney lowe, Hannah, Epsom and St Helier University Hospital NHS Trust, London, United Kingdom
  • Stern, Simon C., Epsom and St Helier University Hospital NHS Trust, London, United Kingdom
  • Winn, Simon K., Epsom and St Helier University Hospital NHS Trust, London, United Kingdom
Introduction


The incidence of hypereosinophilia (>2 x 109/L) in our haemodialysis population in London over the last 13 years is 9.7 per 100 patients per year. We present 9 cases of significant hypereosinophilia which occured alongside significant haemodynamic instability during haemodialysis (HD) sessions.

Case Description

All the patients survived these episodes; 7 of 9 had prompt reduction in eosinophil counts following high dose corticosteroids. All patients were on haemodiafiltration, with ultra-pure water. There was a high recurrence rate following wean of steroid treatment. Adaptations to the HD circuits including changing the line lock, dialyser type and dialyser surface area were made, but the inconsistent response suggests more than bioincompatibility. We did specific allergy testing for ethylene oxide (ETO), latex and chlorhexidine in 3 patients, 1 of which raised to latex. All 9 patients were ANCA negative, Hepatitis B, C and HIV negative. 1 patient had positive strongyloides serology.

Discussion


The reason for the hypereosinophilia is unclear, but it has made HD challenging in these patients. It is possible that there may be other precipitants not related to the HD circuit. Joint management between nephrologists, haematologists and HD unit staff is important for the management of hypereosinophilic patients experiencing severe haemodynamic instability during HD.

Investigations for patients 1-9
PatientPeak eosinophil count (X10<9>/L) Normal range: <0.4 X10<9>/LMast cell tryptase (μmol/L) Normal range: 2- 14 μmol/LTotal IgE (kUA/L) Normal range: <75 kUA/LBMAT, FIP1L1-PDGRFA performed (Y/N)Cause of end stage renal failureDialysis accessACEi or ARB therapy (Y/N)CT scan performed (Y/N)
111.6  NPresumed diabetesAVFYN
220.97.9 Y - no clonal abnormalityPresumed diabetesRIJTLNY
315.516.2864NPresumed diabetesAVGYN
436.114.7 Y - no clonal abnormalityMPGNRIJTLNY
57.911.9<2Y - no clonal abnormalityUnknownRIJTLYN
633.1101220Y - no clonal abnormalityUnknownRIJTLNY
75.68.2238NUnknownRIJTLYN
820.1  NAmyloidosisAVFYY
920.320.31628Y - no clonal abnormalityFSGSRIJTLYN

BMAT: bone marrow aspirate trephine, ACEi: Angiotensin converting enzyme inhibitor, ARB: Angiotensin receptor blocker, MPGN: membranoproliferative glomerulonephritis, FSGS: focal segmental glomerulosclerosis, RIJTL: right internal jugular tunnelled line, AVF: arteriovenous fistula, AVG: arteriovenous graft,

Patient 6